Please ensure Javascript is enabled for purposes of website accessibility

Is Now the Perfect Time to Buy Juno Therapeutics Stock?

By George Budwell - Updated Dec 12, 2017 at 7:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Juno Therapeutics has now gained more than 211% in value this year. Can this red-hot cancer stock keep pushing higher in 2018?

What happened

Juno Therapeutics (JUNO), a clinical-stage oncology company, continued its unrelenting rally this year by tacking on another $5 billion to its market cap in November, according to data from S&P Global Market Intelligence. Juno's market capitalization has thus risen by a whopping $4.6 billion since the start of 2017.

The overarching catalyst behind Juno's surge higher has been the rapid clinical progress of its lead CAR-T therapy, JCAR017, as a potential treatment for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). During the company's third-quarter conference call, the biotech's management noted that JCAR017 produced an exceptional overall response rate of 80% in a small, early stage trial. Even more critically, JCAR017's safety profile was also among the best ever reported for a CAR-T therapy.    

A human T-cell.

Image Source: Getty Images.

So what

Juno is attempting to overcome the first-mover advantage of both Gilead Sciences and Novartis by bringing a safer, and more potent, CAR-T therapy to market. Whether Juno can achieve this all-important goal remains to be seen, but JCAR017's early stage data are on the right track. 

Now what

Juno is pushing JCAR017 as hard as it can in an effort to catch up to Gilead and Novartis. As a result, the biotech is aiming to have JCAR017 approved for advanced NHL by as early as 2018. And if this rather aggressive timeline holds, Juno should be able to push even higher next year. As a leader in the adoptive cell therapy space, after all, this biotech would arguably be pursuing a commercial opportunity that dwarfs its current market cap of roughly $6.7 billion. So this red-hot biotech is arguably still worth checking out -- if not outright owning -- because of its longer-term value proposition.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.
JUNO
Novartis AG Stock Quote
Novartis AG
NVS
$85.68 (0.12%) $0.10
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.96 (0.82%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.